Regression of Choroidal Neovascularization in a Choroideremia Patient after Intravitreal Bevacizumab Injection: A Case Report.
10.3341/jkos.2011.52.6.742
- Author:
Deok Bae KIM
1
;
Mu O JUNG
;
Sung Won CHO
;
Gwang Ju CHOI
;
Dae Hyun KIM
Author Information
1. Happy Eye Clinic, Gwangju, Korea.
- Publication Type:Case Report
- Keywords:
Bevacizumab;
Choroideremia;
Neovascularization
- MeSH:
Adult;
Antibodies, Monoclonal, Humanized;
Atrophy;
Choroid;
Choroidal Neovascularization;
Choroideremia;
Eye;
Fluorescein;
Follow-Up Studies;
Hemorrhage;
Humans;
Male;
Retinal Pigment Epithelium;
Sample Size;
Tomography, Optical Coherence;
Vision, Ocular;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2011;52(6):742-745
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report the first domestic case of choroidal neovascularization in a choroideremia patient treated with intravitreal bevacizumab injection. CASE SUMMARY: A 29-year-old male presented with a sudden decline in vision in the left eye. Fundus examination revealed areas of choriocapillaries and retinal pigment epithelium atrophy with macular hemorrhage. Fluorescein angiogram revealed vascular hyperfluorescence in the juxtafoveal area. Neurosensory detachment around the macula and increased central macular thickness was also observed using optical coherence tomography. Upon the diagnosis of choroideremia with choroidal neovascularization, the patient was treated with 1.25 mg intravitreal bevacizumab. Visual acuity improved after four injections of intravitreal Bevacizumab with improvement in both detachment and fluorescein leakage. CONCLUSIONS: In patients with choroideremia presenting sudden decline in vision, ophthalmologists should detect for possible choroidal neovascularization. The results from the present study show that judicious use of intravitreal Bevacizumab may be effective in such cases. Further studies with a large sample size and sufficiently long follow-up periods are required.
